Tower Research Capital LLC TRC Sells 259 Shares of Integra Lifesciences Holdings Corp (NASDAQ:IART)

Tower Research Capital LLC TRC reduced its holdings in shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) by 31.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 555 shares of the life sciences company’s stock after selling 259 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Integra Lifesciences were worth $33,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the company. First National Bank of Omaha raised its holdings in shares of Integra Lifesciences by 1.7% in the 3rd quarter. First National Bank of Omaha now owns 41,755 shares of the life sciences company’s stock worth $2,508,000 after acquiring an additional 711 shares during the last quarter. Mackay Shields LLC purchased a new stake in shares of Integra Lifesciences in the third quarter worth approximately $1,739,000. Synovus Financial Corp purchased a new stake in shares of Integra Lifesciences in the third quarter worth approximately $553,000. California Public Employees Retirement System lifted its holdings in shares of Integra Lifesciences by 86.6% in the third quarter. California Public Employees Retirement System now owns 151,644 shares of the life sciences company’s stock valued at $9,109,000 after purchasing an additional 70,386 shares in the last quarter. Finally, State of Tennessee Treasury Department lifted its holdings in shares of Integra Lifesciences by 159.9% in the third quarter. State of Tennessee Treasury Department now owns 103,941 shares of the life sciences company’s stock valued at $6,244,000 after purchasing an additional 63,941 shares in the last quarter. Hedge funds and other institutional investors own 80.11% of the company’s stock.

In other Integra Lifesciences news, major shareholder Richard E. Caruso sold 520,000 shares of Integra Lifesciences stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $60.97, for a total value of $31,704,400.00. Following the sale, the insider now owns 134,134 shares of the company’s stock, valued at $8,178,149.98. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP John Mooradian sold 9,249 shares of Integra Lifesciences stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $62.53, for a total transaction of $578,339.97. Following the completion of the sale, the vice president now directly owns 18,706 shares in the company, valued at approximately $1,169,686.18. The disclosure for this sale can be found here. 4.50% of the stock is currently owned by insiders.

IART has been the subject of several recent research reports. Oppenheimer set a $68.00 price target on Integra Lifesciences and gave the stock a “buy” rating in a report on Friday, October 25th. BidaskClub raised shares of Integra Lifesciences from a “sell” rating to a “hold” rating in a report on Thursday, November 21st. TheStreet lowered shares of Integra Lifesciences from an “a-” rating to a “c+” rating in a research note on Thursday, October 24th. ValuEngine lowered shares of Integra Lifesciences from a “sell” rating to a “strong sell” rating in a research note on Thursday, November 14th. Finally, Wells Fargo & Co set a $62.00 target price on shares of Integra Lifesciences and gave the company a “hold” rating in a report on Friday, October 25th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and six have given a buy rating to the company’s stock. Integra Lifesciences has an average rating of “Hold” and a consensus price target of $62.20.

Shares of Integra Lifesciences stock opened at $61.68 on Friday. The business’s fifty day simple moving average is $59.38 and its 200 day simple moving average is $57.52. The company has a current ratio of 2.92, a quick ratio of 1.92 and a debt-to-equity ratio of 1.07. Integra Lifesciences Holdings Corp has a 12 month low of $42.14 and a 12 month high of $65.09. The firm has a market capitalization of $5.24 billion, a P/E ratio of 25.49, a price-to-earnings-growth ratio of 1.80 and a beta of 1.11.

Integra Lifesciences (NASDAQ:IART) last announced its quarterly earnings data on Thursday, October 24th. The life sciences company reported $0.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.03. The firm had revenue of $379.10 million during the quarter, compared to the consensus estimate of $376.85 million. Integra Lifesciences had a return on equity of 16.83% and a net margin of 3.99%. The business’s revenue for the quarter was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.59 EPS. Analysts predict that Integra Lifesciences Holdings Corp will post 2.74 EPS for the current fiscal year.

Integra Lifesciences Company Profile

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Featured Story: Rule of 72

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra Lifesciences Holdings Corp (NASDAQ:IART).

Institutional Ownership by Quarter for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.